EE9600121A - Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid - Google Patents

Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid

Info

Publication number
EE9600121A
EE9600121A EE9600121A EE9600121A EE9600121A EE 9600121 A EE9600121 A EE 9600121A EE 9600121 A EE9600121 A EE 9600121A EE 9600121 A EE9600121 A EE 9600121A EE 9600121 A EE9600121 A EE 9600121A
Authority
EE
Estonia
Prior art keywords
disclosed
differentiation
methods
growth
mgdfs
Prior art date
Application number
EE9600121A
Other languages
English (en)
Estonian (et)
Inventor
D. Bartley Timothy
M. Bogenberger Jakob
A. Bosselman Robert
B. Kinstler Olaf
B. Samal Babru
Hunt Pamela
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/321,488 external-priority patent/US5795569A/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of EE9600121A publication Critical patent/EE9600121A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EE9600121A 1994-03-31 1995-03-30 Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid EE9600121A (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22176894A 1994-03-31 1994-03-31
US25262894A 1994-05-31 1994-05-31
US08/321,488 US5795569A (en) 1994-03-31 1994-10-12 Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US34778094A 1994-11-30 1994-11-30
PCT/US1995/003776 WO1995026746A1 (en) 1994-03-31 1995-03-30 Compositions and methods for stimulating megakaryocyte growth and differentiation

Publications (1)

Publication Number Publication Date
EE9600121A true EE9600121A (et) 1997-04-15

Family

ID=27499246

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600121A EE9600121A (et) 1994-03-31 1995-03-30 Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid

Country Status (32)

Country Link
US (1) US5766581A (cs)
EP (3) EP0675201A1 (cs)
JP (2) JP2996415B2 (cs)
KR (2) KR100203824B1 (cs)
CN (2) CN1229385C (cs)
AT (1) ATE169335T1 (cs)
AU (1) AU691606B2 (cs)
BG (1) BG62685B1 (cs)
BR (1) BR9506017A (cs)
CA (1) CA2167090C (cs)
CZ (2) CZ288926B6 (cs)
DE (1) DE69503849T2 (cs)
DK (1) DK0690127T3 (cs)
EE (1) EE9600121A (cs)
ES (1) ES2119250T3 (cs)
FI (1) FI960136A7 (cs)
GE (1) GEP20002180B (cs)
GR (1) GR3027593T3 (cs)
HK (1) HK1041275B (cs)
HU (1) HU218893B (cs)
IL (1) IL113206A0 (cs)
LV (2) LV11783B (cs)
MY (1) MY113048A (cs)
NO (1) NO960111L (cs)
NZ (1) NZ283863A (cs)
PL (1) PL182567B1 (cs)
RO (1) RO115788B1 (cs)
SI (1) SI0690127T1 (cs)
SK (1) SK166695A3 (cs)
TW (3) TW496870B (cs)
WO (1) WO1995026746A1 (cs)
YU (1) YU20095A (cs)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU4163196A (en) * 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
US5986049A (en) * 1994-12-30 1999-11-16 Zymogenetics, Inc. Purified thrombopoietin and method of making it
TW387940B (en) * 1995-01-17 2000-04-21 Kirin Brewery Anti-tpo monodonal antibody
WO1996023888A1 (en) 1995-02-03 1996-08-08 G.D. Searle & Co. NOVEL c-MPL LIGANDS
US5696250A (en) 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
DE69636052T2 (de) * 1995-02-15 2007-04-12 Amgen Inc., Thousand Oaks Mpl-liganden analoga
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TR199701526T1 (xx) 1995-06-07 1998-03-21 Glaxo Group Limited Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler.
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
EP0870027A1 (en) * 1995-10-05 1998-10-14 G.D. Searle & Co. Novel c-mpl receptor agonists
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
CN1142940C (zh) * 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
US5914251A (en) * 1996-10-22 1999-06-22 Amgen Inc. Nucleic acid molecules encoding placental-derived growth factors
AU2006201129B2 (en) * 1997-05-21 2008-03-13 Genentech, Inc. Novel administration of thrombopoietin
WO1998052598A1 (en) * 1997-05-21 1998-11-26 Genentech, Inc. Novel administration of thrombopoietin
UA79430C2 (en) * 1998-04-28 2007-06-25 Applied Research Systems Method for the stepwise attachment of polyethylene glycol to polypeptide
US20030228666A1 (en) 1998-06-30 2003-12-11 Daewoong Pharmaceutical Co., Ltd. Novel human thrombopoietin mutein
TWI257394B (en) 1998-10-23 2006-07-01 Kirin Amgen Inc Thrombopoietic compounds
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000057891A1 (en) 1999-03-30 2000-10-05 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
DE60142239D1 (de) 2000-08-11 2010-07-08 Kyowa Hakko Kirin Co Ltd DEN PHOSPHORSÄURE-METABOLISMUS, DEN KALZIUM-METABOLISMUS, VERKALKUNG UND DEN VITAMIN D-METABOLISMUS KONTROLLIERENDE POLYPEPTIDE SOWIE FüR DIESE KODIERENDE DNA-MOLEKÜLE
AU2001280161A1 (en) * 2000-08-24 2002-03-04 Kirin Beer Kabushiki Kaisha C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
UY26317A1 (es) * 2000-08-30 2000-10-31 Alfonso Cayota Carlos Pritsch Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
AU2003276846A1 (en) * 2002-08-09 2004-02-25 Xencor Thrombopoiesis-stimulating proteins having reduced immunogenicity
CA2499625A1 (en) 2002-09-18 2004-04-01 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
PT1667708E (pt) * 2002-12-26 2012-09-14 Mountain View Pharmaceuticals Conjugados de interferão-beta-1b e polietileno glicol apresentando uma potência biológica in vitro aumentada
PL378134A1 (pl) * 2003-02-11 2006-03-06 Irm Llc Nowe pochodne bicykliczne i kompozycje farmaceutyczne zawierające pochodne bicykliczne
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
CA2520875A1 (en) * 2003-03-31 2004-10-21 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
EP1675606B1 (en) 2003-08-28 2017-04-05 Janssen Pharmaceuticals, Inc. Peptides and compounds that bind to thrombopoietin receptors
EP2327723A3 (en) 2003-10-10 2012-06-27 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
JP4903580B2 (ja) 2003-12-30 2012-03-28 アウグスティヌス・バーダー 組織再生法
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
WO2006019950A2 (en) * 2004-07-16 2006-02-23 Nektar Therapeutics Al, Corporation Conjugates of a gm-csf moiety and a polymer
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
DE602005024599D1 (de) * 2004-10-25 2010-12-16 Ligand Pharm Inc Verbindungen modulierende thrombopoietinaktivität und verfahren
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US8318153B2 (en) * 2006-06-29 2012-11-27 Nalin David R Method of medically treating an individual
AU2008262490B2 (en) 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
SG187427A1 (en) 2008-04-14 2013-02-28 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
CA2746181C (en) 2008-12-09 2016-03-15 Halozyme, Inc. Extended soluble ph20 polypeptides and uses thereof
US8686175B2 (en) 2008-12-16 2014-04-01 Dow Corning Corporation Preparation of siloxanes
US20110294733A1 (en) 2009-01-20 2011-12-01 Hanall Biopharma Co., Ltd. Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
PL3127427T3 (pl) 2009-05-29 2020-06-15 Novartis Ag Sposoby podawania związków agonistów trombopoetyny
DK2477603T3 (en) 2009-09-17 2016-06-13 Baxalta Inc STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
KR20130125753A (ko) 2010-07-20 2013-11-19 할로자임, 아이엔씨 항-히알루로난제 투여와 관련된 유해 부작용의 치료
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012174480A2 (en) 2011-06-17 2012-12-20 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
WO2013063155A2 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
PL2833905T3 (pl) 2012-04-04 2019-01-31 Halozyme, Inc. Terapia skojarzona hialuronidazą i taksanem ukierunkowanym na guza
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
PL3186281T3 (pl) 2014-08-28 2019-10-31 Halozyme Inc Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
SG10202110500TA (en) 2017-06-22 2021-11-29 Catalyst Biosciences Inc Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
BR112021012601A2 (pt) 2018-12-28 2021-11-30 Catalyst Biosciences Inc Polipeptídeos ativadores de plasminogênio do tipo uroquinase modificados e métodos de uso
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4894440A (en) * 1986-09-17 1990-01-16 Massachusetts Institute Of Technology Method of isolating megakaryocyte stimulatory factor
ZA887773B (en) * 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
IL90719A0 (en) * 1988-06-28 1990-01-18 Yissum Res Dev Co Novel nuclei acids and polypeptides encoded thereby
US5128449A (en) * 1988-07-05 1992-07-07 The University Of Tennessee Research Corporation Polypeptide and a method for its production
EP0516845B1 (en) * 1988-09-21 1997-06-18 Meiji Seika Kaisha Ltd. Novel megakaryocytic colony stimulating factor and process for its preparation
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5087448A (en) * 1989-02-02 1992-02-11 The Board Of Regents Of The University Of Oklahoma Enhancing growth of megakaryocytes in mammals using interleuking 6
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
JPH04506513A (ja) * 1989-04-03 1992-11-12 ジェネティックス・インスティテュート・インコーポレイテッド 巨核球増殖促進活性
US5260417A (en) * 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
DE69029040T2 (de) * 1989-08-08 1997-02-27 Genetics Inst Megakaryocytopoietischer faktor
US6433142B1 (en) * 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
AU7972991A (en) * 1990-05-31 1991-12-31 Meiji Seika Kaisha Ltd. Novel megakaryocyte colony stimulating factor and production thereof
WO1992000319A1 (en) * 1990-07-02 1992-01-09 Hipple Cancer Research Center Human meg-csf protein and methods
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
KR927003795A (ko) * 1990-10-05 1992-12-18 시스테믹스, 인코포레이티드 거핵세포 및 혈소판 성장, 제조방법 및 이것들을 포함하는 조성물
CA2071479A1 (en) * 1990-10-12 1992-04-13 Pamela Hunt Megakaryocyte maturation factors
WO1992007074A1 (fr) * 1990-10-19 1992-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide de la famille d'un recepteur de facteur de croissance, application au diagnostic et a la therapie des maladies myeloproliferatives
AU646530B2 (en) * 1990-12-28 1994-02-24 Asahi Kasei Kogyo Kabushiki Kaisha Novel megakaryocyte amplifier and production thereof
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JPH04295500A (ja) * 1991-03-26 1992-10-20 Asahi Chem Ind Co Ltd 新規な巨核球増幅因子とその製法
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
WO1993000433A1 (en) * 1991-06-28 1993-01-07 New England Deaconess Hospital A differentiated megakaryocyte line producing novel megakaryocyte differentiation factors
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
JP3328341B2 (ja) * 1991-12-27 2002-09-24 中外製薬株式会社 新規な巨核球増幅因子
AU3463493A (en) * 1992-02-07 1993-09-03 Asahi Kasei Kogyo Kabushiki Kaisha Novel megakaryocyte amplifier and production thereof
AU4190893A (en) * 1992-07-17 1994-01-20 Suntory Limited Megakaryocyte differentiation factor
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
KR100289201B1 (ko) * 1994-02-14 2001-05-02 엘. 데이예를 카렌. 조혈 단백질과 그것의 제조를 위한 재료 및 방법
EP0723456A1 (en) * 1994-02-14 1996-07-31 The University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
SG79882A1 (en) * 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
US5547931A (en) * 1994-02-23 1996-08-20 Immtech International Inc. Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets

Also Published As

Publication number Publication date
MX9600206A (es) 1998-11-30
HK1004231A1 (en) 1998-11-20
KR100303810B1 (ko) 2001-12-01
CN1322759A (zh) 2001-11-21
TW496870B (en) 2002-08-01
LV12275A (lv) 1999-05-20
MY113048A (en) 2001-11-30
BG62685B1 (bg) 2000-05-31
CZ288890B6 (cs) 2001-09-12
YU20095A (sh) 1998-08-14
LV11783B (en) 1997-12-20
FI960136L (fi) 1996-03-11
NO960111D0 (no) 1996-01-10
IL113206A0 (en) 1995-06-29
HK1041275A1 (en) 2002-07-05
RO115788B1 (ro) 2000-06-30
LV12275B (en) 1999-08-20
AU2230895A (en) 1995-10-23
SI0690127T1 (en) 1998-12-31
EP0690127A1 (en) 1996-01-03
DK0690127T3 (da) 1999-05-03
HU218893B (hu) 2000-12-28
CN1137757A (zh) 1996-12-11
NZ283863A (en) 1997-12-19
PL182567B1 (pl) 2002-01-31
LV11783A (lv) 1997-06-20
CA2167090A1 (en) 1995-10-12
EP0675201A1 (en) 1995-10-04
EP0690127B1 (en) 1998-08-05
CZ288926B6 (cs) 2001-09-12
JPH10510980A (ja) 1998-10-27
BG100625A (bg) 1997-04-30
CZ350595A3 (en) 1997-01-15
GR3027593T3 (en) 1998-11-30
DE69503849D1 (de) 1998-09-10
HUT74257A (en) 1996-11-28
JP2996415B2 (ja) 1999-12-27
EP0755263A4 (en) 2005-02-09
AU691606B2 (en) 1998-05-21
WO1995026746A1 (en) 1995-10-12
EP0755263A1 (en) 1997-01-29
FI960136A7 (fi) 1996-03-11
FI960136A0 (fi) 1996-01-11
BR9506017A (pt) 1997-10-14
HU9600059D0 (en) 1996-03-28
JP2000103799A (ja) 2000-04-11
HK1041275B (zh) 2006-07-28
CA2167090C (en) 2002-05-14
SK166695A3 (en) 1997-02-05
ES2119250T3 (es) 1998-10-01
PL312577A1 (en) 1996-04-29
JP3485842B2 (ja) 2004-01-13
TW414799B (en) 2000-12-11
DE69503849T2 (de) 1999-04-01
TW565568B (en) 2003-12-11
KR100203824B1 (ko) 1999-06-15
CN1103782C (zh) 2003-03-26
ATE169335T1 (de) 1998-08-15
CN1229385C (zh) 2005-11-30
US5766581A (en) 1998-06-16
NO960111L (no) 1996-09-24
GEP20002180B (en) 2000-07-25

Similar Documents

Publication Publication Date Title
EE9600121A (et) Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid
Munksgaard et al. Collagen synthesis and secretion by rat incisor odontoblasts in organ culture
DK0473724T3 (da) Et humant cytokin, interleukin-9
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
MX9602259A (es) Proteina modificada quimicamente en el nitrogeno terminal, composiciones que las incluyen y metodos para su preparacion.
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
DE3584460D1 (de) Verfahren zur erhoehung der ausbeute von heterologen proteinen, produziert durch zuechtung von rekombinanten bakterien.
DK1200561T3 (da) Rekombinant stabil celleklon, dens fremstilling og anvendelse
ATE174756T1 (de) Zyklische anti-tumorpromotor-verbindungen, zusammensetzungen und verfahren zur herstellung sowie ihre verwendung
DE69935071D1 (de) Mutein von humanem Thrombopoietin
DE69022121D1 (de) Verfahren zur Herstellung eines Metastaseninhibitorenfaktors.
DE69032471D1 (de) Proteine mit onkostatin-m-aktivität und verfahren zu ihrer herstellung
ES8705466A1 (es) Un metodo para la preparacion del factor nkbs regulador del cancer humano.
ES2004438A6 (es) Un metodo para producir una proteina trombolitica